Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Out, H. J.
Right arrow Articles by de Laat, W. N.G.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Out, H. J.
Right arrow Articles by de Laat, W. N.G.M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 14, No. 9, 2189-2190, September 1999
© 1999 European Society of Human Reproduction and Embryology

Debate Continued

What are the clinical benefits of recombinant gonadotrophins?

The development of recombinant FSH (Puregon®): a scientific business

Henk J. Out1, 3, Herjan J.T.Coelingh Bennink2 and Willem N.G.M. de Laat2

1 Organon Laboratories Ltd, Science Park, Milton Road, Cambridge CB4 0FL, UK, and 2 NV Organon, Oss, The Netherlands

The debate on the clinical benefits of recombinant gonadotrophins (Meniru, 1999Go) addressed various aspects of recombinant follicle stimulating hormone (FSH) in general, and follitrophin ß (Puregon®; NV Organon, Oss, The Netherlands) in particular, and has prompted us to participate in this discussion. Although, as manufacturers of this preparation, we do not wish to interfere in a scientific debate amongst clinicians on the value of this compound, we feel the need to put a number of the issues raised by Meniru in the right context. Balen et al. (1999) and Bergh (1999) have already addressed many of these issues in reaction to the leading . . . [Full Text of this Article]

Notes

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
J.E.F. Zwart-van Rijkom, F.J. Broekmans, and H.G.M. Leufkens
From HMG through purified urinary FSH preparations to recombinant FSH: a substitution study
Hum. Reprod., April 1, 2002; 17(4): 857 - 865.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
P.M.G. Bouloux, D.J. Handelsman, F. Jockenhovel, E. Nieschlag, J. Rabinovici, W.L.H. Frasa, J.J. de Bie, G. Voortman, and J. Itskovitz-Eldor
First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males
Hum. Reprod., August 1, 2001; 16(8): 1592 - 1597.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
E.R. Hernandez
The clinical benefits of recombinant gonadotrophins
Hum. Reprod., March 1, 2000; 15(3): 734 - 735.
[Full Text] [PDF]